Natalia A. Chertova
Natalia A. Chertova has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- E. D. Mytsa
Scientific Centre for Expert Evaluation of Medicinal Products
2 shared publications - Marina A. Engibaryan
National Medical Research Centre for Oncology
2 shared publications - Vadim Anatolievich Merkulov
Scientific Centre for Expert Evaluation of Medicinal Products
2 shared publications - Рауза Асхатовна Волкова
Scientific Centre for Expert Evaluation of Medicinal Products
2 shared publications - A. S. Binyatova
Scientific Centre for Expert Evaluation of Medicinal Products
1 shared publication A. S. Sukhno
Федеральное государственное бюджетное учреждение «Научный центр экспертизы средств медицинского применения» Министерства здравоохранения Российской Федерации
1 shared publication
Latest Publications
- 15 December 2024
- Published by Paediatrician Publishers LLC in Annals of the Russian academy of medical sciences
- Vol. 79 (6) , 490-506
Genetic and epigenetic predictors of tongue squamous cell carcinoma sensitivity to platinum drugs
Background. Treatment of locally advanced malignant tumors of the tongue at the present stage of development of clinical oncology is a difficult task and is an important problem in oncology. The aim — to screen for genetic and epigenetic predictors of locally advanced tongue cancer sensitivity to platinum therapy. Methods. A comprehensive clinical and molecular genetic examination was carried out in 100 patients with locally advanced malignant tumors of the tongue, as well as 30 donors without oncological pathology. The study used a new method for the treatment of locally advanced squamous cell carcinoma of the tongue using 2-stage superselective embolization as a component of complex treatment. At the first stage, a screening bioinformatics analysis was carried out to form a panel of genetic loci associated with sensitivity to therapy with platinum drugs. The determination of the relative copy number and expression of these loci responsible for repair and for the proliferation regulation and apoptosis was performed by Real-Time qPCR. Results. Integration of RNA-seq datasets, copy number variation data, and relevant clinicopathological information from TCGA and GEO databases allowed us to identify 65 genetic loci associated with sensitivity to platinum therapy. These genes were validated in patient biological material. Laboratory screening showed differential expression of BRCA1, BLM, ERCC1, EXO1, RAD50, PIF1, LIG1, BCL2, ERBB2, MAGEH1, NGFRAP1, and CASP8 genes, correlating with changes in their tissue copy numbers, between groups of patients sensitive and resistant to platinum therapy. The profile of gene copy numbers of BRCA1, BLM, EXO1, RAD50, PIF1, LIG1, CASP8, MAGEH1 and NGFRAP1 was detected in the blood plasma of patients with squamous cell carcinoma of the tongue, which was differential for two groups of patients — sensitive and resistant to platinum therapy. Based on bootstrap models, the final gene panel was obtained: BLM/NGFRAP1, BRCA1/MAGEH1, EXO1/RAD50, BLM/CASP8, BRCA1/RAD50 and BRCA1/EXO1, providing diagnostic sensitivity at the level of 95% and specificity at the level of 90% (AUC 0.98) when dividing patients into a group sensitive and resistant to platinum therapy. Conclusion. Comprehensive bioinformatics analysis of RNA sequencing data, gene copy number data, and clinical and pathological information from the TCGA and GEO databases, as well as laboratory screening of potential predictors, allowed us to obtain a panel of genes — BLM/NGFRAP1, BRCA1/MAGEH1, EXO1/RAD50, BLM/CASP8, BRCA1/RAD50, and BRCA1/EXO1, the combination of which provides high diagnostic sensitivity and specificity in dividing patients into a group susceptible and resistant to platinum therapy.
- 15 December 2024
- Published by Paediatrician Publishers LLC in Annals of the Russian academy of medical sciences
- Vol. 79 (6) , 490-506
Genetic and epigenetic predictors of tongue squamous cell carcinoma sensitivity to platinum drugs
Background. Treatment of locally advanced malignant tumors of the tongue at the present stage of development of clinical oncology is a difficult task and is an important problem in oncology. The aim — to screen for genetic and epigenetic predictors of locally advanced tongue cancer sensitivity to platinum therapy. Methods. A comprehensive clinical and molecular genetic examination was carried out in 100 patients with locally advanced malignant tumors of the tongue, as well as 30 donors without oncological pathology. The study used a new method for the treatment of locally advanced squamous cell carcinoma of the tongue using 2-stage superselective embolization as a component of complex treatment. At the first stage, a screening bioinformatics analysis was carried out to form a panel of genetic loci associated with sensitivity to therapy with platinum drugs. The determination of the relative copy number and expression of these loci responsible for repair and for the proliferation regulation and apoptosis was performed by Real-Time qPCR. Results. Integration of RNA-seq datasets, copy number variation data, and relevant clinicopathological information from TCGA and GEO databases allowed us to identify 65 genetic loci associated with sensitivity to platinum therapy. These genes were validated in patient biological material. Laboratory screening showed differential expression of BRCA1, BLM, ERCC1, EXO1, RAD50, PIF1, LIG1, BCL2, ERBB2, MAGEH1, NGFRAP1, and CASP8 genes, correlating with changes in their tissue copy numbers, between groups of patients sensitive and resistant to platinum therapy. The profile of gene copy numbers of BRCA1, BLM, EXO1, RAD50, PIF1, LIG1, CASP8, MAGEH1 and NGFRAP1 was detected in the blood plasma of patients with squamous cell carcinoma of the tongue, which was differential for two groups of patients — sensitive and resistant to platinum therapy. Based on bootstrap models, the final gene panel was obtained: BLM/NGFRAP1, BRCA1/MAGEH1, EXO1/RAD50, BLM/CASP8, BRCA1/RAD50 and BRCA1/EXO1, providing diagnostic sensitivity at the level of 95% and specificity at the level of 90% (AUC 0.98) when dividing patients into a group sensitive and resistant to platinum therapy. Conclusion. Comprehensive bioinformatics analysis of RNA sequencing data, gene copy number data, and clinical and pathological information from the TCGA and GEO databases, as well as laboratory screening of potential predictors, allowed us to obtain a panel of genes — BLM/NGFRAP1, BRCA1/MAGEH1, EXO1/RAD50, BLM/CASP8, BRCA1/RAD50, and BRCA1/EXO1, the combination of which provides high diagnostic sensitivity and specificity in dividing patients into a group susceptible and resistant to platinum therapy.
- Open Access
- 28 April 2022
- Published by ANO -Perspective of Oncology in South Russian Journal of Cancer
- Vol. 3 (2) , 31-40
Modern diagnostic and treatment methods in paranasal sinus malignant tumors
Malignant tumors of the head and neck are still one of the most challenging problems of treatment in modern oncology. The disease affects mainly the capable people (from 30 to 60 years old). Tumor lesions of the paranasal sinuses lead to disability and have a high mortality rate. Head and neck tumors comprise of 20–30 % of all cancer cases. People with early paranasal sinus cancer have minor complaints, their general condition doesn’t get affected so they don’t seek for medical care in a while. As a result, patients start on treatment at tumor grades III–IV. This article provides the most complete information about the causes, frequency and special features of the course of paranasal sinus cancer, as well as about modern methods of it’s diagnosis and combination treatment. Despite the great advances in the treatment of these malignant tumors the three and five year survival rates remain unsatisfactory, which requires a research for new effective treatments. Currently the main treatment methods for these malignant tumors are combination and complex (involving surgery, radiotherapy and chemotherapy) treatments. The standard treatment approach includes radical surgical removal of the primary tumor and metastatic lymph nodes followed by radiation or chemoradiation therapy. Chemotherapy as monotherapy is administered in non-resectable primary or recurrent tumors, distant metastases or when a patient refuses the radical surgery. Improvement of existing treatment methods and development of new ones are an essential need. Earlier detection of the disease requires primary care physicians to be trained to diagnose tumor lesions of the paranasal sinuses, and highly specialized physicians (dentists, otorhinolaryngologists, maxillofacial surgeons, dermatologists) to express their cancer alertness.
- 28 April 2022
- Published by ANO -Perspective of Oncology in South Russian Journal of Cancer
- Vol. 3 (2) , 31-40
Open AccessModern diagnostic and treatment methods in paranasal sinus malignant tumors
Malignant tumors of the head and neck are still one of the most challenging problems of treatment in modern oncology. The disease affects mainly the capable people (from 30 to 60 years old). Tumor lesions of the paranasal sinuses lead to disability and have a high mortality rate. Head and neck tumors comprise of 20–30 % of all cancer cases. People with early paranasal sinus cancer have minor complaints, their general condition doesn’t get affected so they don’t seek for medical care in a while. As a result, patients start on treatment at tumor grades III–IV. This article provides the most complete information about the causes, frequency and special features of the course of paranasal sinus cancer, as well as about modern methods of it’s diagnosis and combination treatment. Despite the great advances in the treatment of these malignant tumors the three and five year survival rates remain unsatisfactory, which requires a research for new effective treatments. Currently the main treatment methods for these malignant tumors are combination and complex (involving surgery, radiotherapy and chemotherapy) treatments. The standard treatment approach includes radical surgical removal of the primary tumor and metastatic lymph nodes followed by radiation or chemoradiation therapy. Chemotherapy as monotherapy is administered in non-resectable primary or recurrent tumors, distant metastases or when a patient refuses the radical surgery. Improvement of existing treatment methods and development of new ones are an essential need. Earlier detection of the disease requires primary care physicians to be trained to diagnose tumor lesions of the paranasal sinuses, and highly specialized physicians (dentists, otorhinolaryngologists, maxillofacial surgeons, dermatologists) to express their cancer alertness.
- Open Access
- 20 December 2018
- Published by SCEEMP in Biological Products. Prevention, Diagnosis, Treatment
- Vol. 18 (4) , 249-256
Using Real-Time RT-PCR Reagent Kits for Identity Testing of Measles, Mumps and Rubella Vaccines
Currently, the identity of measles, mumps and rubella virus vaccines is determined during certification testing by a labour-consuming, lengthy and costly neutralisation test using cell cultures. The identity of the virus contained in such vaccines is established based on neutralisation of cytopathic effect of viruses in sensitive RK-13 and Vero cell cultures using a specific immune serum. An urgent challenge is to simplify and reduce the cost of controlling the identity of commercial batches of measles, mumps and rubella vaccines using polymerase chain reaction (PCR) tests. The aim of the study was to determine the possibility of viral ribonucleic acid (RNA) detection in these vaccines using reagent kits from different manufacturers for detection of measles, mumps and rubella viruses in clinical material by real-time reverse transcription-PCR (RT-PCR). The article presents the results of the study, which assessed the possibility of using the real-time RT-PCR for testing the identity of measles, mumps and rubella viruses in vaccines. The authors of the study analysed domestically produced and foreign reagent kits intended for detection of measles, mumps and rubella viruses in clinical material. All the studied reagent kits were able to detect RNAs of the above-mentioned viruses in vaccine products. All the reagent kits demonstrated high specificity and could be used to confirm the identity of the measles, mumps and rubella viruses in all the studied vaccines. Commercial domestic reagent kits can be used to determine the identity of rubella vaccines by RT-PCR. However, it is advisable to develop domestic reagent kits for checking the identity of measles and mumps vaccines by RT-PCR. The acceptability of the test results was assessed using the industry reference standards of measles, mumps and rubella viruses activity with certified stable activity values.
- 20 December 2018
- Published by SCEEMP in Biological Products. Prevention, Diagnosis, Treatment
- Vol. 18 (4) , 249-256
Open AccessUsing Real-Time RT-PCR Reagent Kits for Identity Testing of Measles, Mumps and Rubella Vaccines
Currently, the identity of measles, mumps and rubella virus vaccines is determined during certification testing by a labour-consuming, lengthy and costly neutralisation test using cell cultures. The identity of the virus contained in such vaccines is established based on neutralisation of cytopathic effect of viruses in sensitive RK-13 and Vero cell cultures using a specific immune serum. An urgent challenge is to simplify and reduce the cost of controlling the identity of commercial batches of measles, mumps and rubella vaccines using polymerase chain reaction (PCR) tests. The aim of the study was to determine the possibility of viral ribonucleic acid (RNA) detection in these vaccines using reagent kits from different manufacturers for detection of measles, mumps and rubella viruses in clinical material by real-time reverse transcription-PCR (RT-PCR). The article presents the results of the study, which assessed the possibility of using the real-time RT-PCR for testing the identity of measles, mumps and rubella viruses in vaccines. The authors of the study analysed domestically produced and foreign reagent kits intended for detection of measles, mumps and rubella viruses in clinical material. All the studied reagent kits were able to detect RNAs of the above-mentioned viruses in vaccine products. All the reagent kits demonstrated high specificity and could be used to confirm the identity of the measles, mumps and rubella viruses in all the studied vaccines. Commercial domestic reagent kits can be used to determine the identity of rubella vaccines by RT-PCR. However, it is advisable to develop domestic reagent kits for checking the identity of measles and mumps vaccines by RT-PCR. The acceptability of the test results was assessed using the industry reference standards of measles, mumps and rubella viruses activity with certified stable activity values.
- Open Access
- 22 June 2018
- Published by SCEEMP in Biological Products. Prevention, Diagnosis, Treatment
- Vol. 18 (2) , 75-80
Molecular-Biological Methods of Quality Control of Biological Active Substances Produced by Recombinant DNA Technology
Биотехнологические препараты, полученные с применением технологии рекомбинантных ДНК, широко используются в настоящее время. В соответствии с международными и отечественными требованиями содержание остаточной ДНК штамма-продуцента в подобных препаратах не должно превышать 10 нг на 1 дозу, для препаратов, предназначенных для частого или длительного введения, эта величина не должна превышать 100 пг на 1 дозу. В статье представлено описание наиболее часто используемых методов определения содержания остаточной ДНК штамма-продуцента в субстанциях биотехнологических препаратов: молекулярная гибридизация с биотиновой или дигоксигениновой меткой ДНК-зонда (полуколичественный метод), система Threshold, ПЦР в режиме реального времени, метод с флуоресцентным реагентом (количественные методы). В случае использования методов с флуоресцентным реагентом или ПЦР в режиме реального времени для замены ранее использовавшегося метода требуется подтверждение их правильности, например с помощью сравнительной оценки содержания остаточной ДНК двумя методами — вновь вводимым и ранее использовавшимся методом. Отмечены преимущества и недостатки методов, источники неопределенности результатов при проведении испытаний, указана необходимость использования стандартных и контрольных образцов, аттестованных в установленном порядке. В субстанциях, внесенных в Государственный реестр лекарственных средств, содержание остаточной ДНК штамма-продуцента соответствует международным рекомендациям.
- 22 June 2018
- Published by SCEEMP in Biological Products. Prevention, Diagnosis, Treatment
- Vol. 18 (2) , 75-80
Open AccessMolecular-Biological Methods of Quality Control of Biological Active Substances Produced by Recombinant DNA Technology
Биотехнологические препараты, полученные с применением технологии рекомбинантных ДНК, широко используются в настоящее время. В соответствии с международными и отечественными требованиями содержание остаточной ДНК штамма-продуцента в подобных препаратах не должно превышать 10 нг на 1 дозу, для препаратов, предназначенных для частого или длительного введения, эта величина не должна превышать 100 пг на 1 дозу. В статье представлено описание наиболее часто используемых методов определения содержания остаточной ДНК штамма-продуцента в субстанциях биотехнологических препаратов: молекулярная гибридизация с биотиновой или дигоксигениновой меткой ДНК-зонда (полуколичественный метод), система Threshold, ПЦР в режиме реального времени, метод с флуоресцентным реагентом (количественные методы). В случае использования методов с флуоресцентным реагентом или ПЦР в режиме реального времени для замены ранее использовавшегося метода требуется подтверждение их правильности, например с помощью сравнительной оценки содержания остаточной ДНК двумя методами — вновь вводимым и ранее использовавшимся методом. Отмечены преимущества и недостатки методов, источники неопределенности результатов при проведении испытаний, указана необходимость использования стандартных и контрольных образцов, аттестованных в установленном порядке. В субстанциях, внесенных в Государственный реестр лекарственных средств, содержание остаточной ДНК штамма-продуцента соответствует международным рекомендациям.